Post hoc analysis of LoDoCo2: discontinuation due to side effects was 4.2% with colchicine vs 4.4% with placebo (HR 0.95, 0.73-1.22) in chronic coronary disease; 9.5% reported side effects in run-in, more often women.
Secondary analysisn = 6,519
Jannink et al. Side Effects of Low-Dose Colchicine in Chronic Coronary Disease: A Post Hoc Analysis of the LoDoCo2 Trial